CAS: 18355-75-4; 2,3-Difluorobenzamide

上下游产品

CAS号21524-39-0 2,3-二氟苯腈

📜2,3-二氟苯甲醛置于叔丁基过氧化氢,Titanium Superoxide,糖精体系中,用 1,4-二氧六环,正己烷 用作溶剂,化学反应 1.0H,以85%的收率获得2,3-二氟苯甲酸
参考文献:以糖精为氮源的钛超氧化物催化醛的氧化酰胺化:伯酰胺的合成
标题:以糖精为氮源的钛超氧化物催化醛的氧化酰胺化:伯酰胺的合成
摘要:已经开发出一种新的多相催化体系(ti-Superoxide/saccharin/tbhp),它可以有效地催化醛的氧化酰胺化以产生各种伯酰胺.该协议采用糖精作为胺源,并被发现可以耐受各种具有不同官能团的底物.中等至优异的收率,催化剂的可重复使用性和操作简单性是主要亮点.还讨论了催化剂在氧化酰胺化中的可能机制和作用.
Doi:10.1039/c9Ra10413E

专利信息

专利号:US-2008045718-A1
优先权日:2006-08-14
标题 :Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives

专利号:WO-2008021235-A2
优先权日:2006-08-14
标 题:Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives

专利号:EP-2069284-A2
优先权日:2006-08-14
标 题:Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives

专利号:US-7985860-B2
优先权日:2006-08-14
标题:Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
发明人：CUTARELLI TIMOTHY D; FU XIAOYONG; MCALLISTER TIMOTHY L; REEDER MICHAEL R; YIN JIANGUO; YONG KELVIN H; ZHANG SHUYI
权利人:SCHERING CORP
摘要:This application discloses a novel process to synthesize 2-(Quinolin-5yo)-4,5-Disubstituted-Azole derivatives, which may be used, for example, as PDE IV inhibitor compounds in pharmaceutical preparations.

专利号:CN-109970674-A
优先权日:2019-03-26
标题:A kind of etoxazole hapten and its synthesis method and application

专利号:WO-2012014127-A1
优先权日:2010-07-30
标 题:5-lipoxygenase inhibitors
发明人：VERMA ASHWANI KUMAR; MALHOTRA SANJAY; GHORPADE SATISH MADHAV; DAWANGE MAHESH BALASAHEB; RAY ABHIJIT; GUPTA SUMAN; SRIVASTAVA PUNIT; DASTIDAR SUNANDA GHOSH
权利人:RANBAXY LAB LTD; VERMA ASHWANI KUMAR; MALHOTRA SANJAY; GHORPADE SATISH MADHAV; DAWANGE MAHESH BALASAHEB; RAY ABHIJIT; GUPTA SUMAN; SRIVASTAVA PUNIT; DASTIDAR SUNANDA GHOSH
摘要:The present invention relates to sulfonamides derivatives as 5-lipoxygenase (5-LO) inhibitors and a process for their synthesis. The present invention also relates to pharmacological compositions containing these sulfonamides derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, Type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders.